Cargando…
Titrating Optimal Dose of Osmotic-Controlled Release Oral Delivery (OROS)-Methylphenidate and Its Efficacy and Safety in Korean Children with ADHD: A Multisite Open Labeled Study
OBJECTIVE: This study was aimed to determine effectiveness and tolerability of Osmotic-controlled Release Oral delivery (OROS) methylphenidate (MPH) and its optimal dose administered openly over a period of up to 12 weeks in drug naïve Korean children with ADHD. METHODS: Subjects (n=143), ages 6 to...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Neuropsychiatric Association
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3440475/ https://www.ncbi.nlm.nih.gov/pubmed/22993525 http://dx.doi.org/10.4306/pi.2012.9.3.257 |
_version_ | 1782243169019101184 |
---|---|
author | Song, Dong-Ho Choi, Soul Joung, Yoo Sook Ha, Eun Hye Kim, Boong-Nyun Shin, Yee-Jin Shin, Dongwon Yoo, Hee Jeong Cheon, Keun-Ah |
author_facet | Song, Dong-Ho Choi, Soul Joung, Yoo Sook Ha, Eun Hye Kim, Boong-Nyun Shin, Yee-Jin Shin, Dongwon Yoo, Hee Jeong Cheon, Keun-Ah |
author_sort | Song, Dong-Ho |
collection | PubMed |
description | OBJECTIVE: This study was aimed to determine effectiveness and tolerability of Osmotic-controlled Release Oral delivery (OROS) methylphenidate (MPH) and its optimal dose administered openly over a period of up to 12 weeks in drug naïve Korean children with ADHD. METHODS: Subjects (n=143), ages 6 to 18-years, with a clinical diagnosis of any subtype of ADHD were recruited from 7 medical centers in Korea. An individualized dose of OROS-MPH was determined for each subject depending on the response criteria. The subjects were assessed with several symptom rating scales in week 1, 3, 6, 9 and 12. RESULTS: 77 of 116 subjects (66.4%) achieved the criteria for response and the average of optimal daily dose for response was to 30.05±12.52 mg per day (0.90±0.31 mg/kg/d) at the end of the study. Optimal dose was not significantly different between ADHD subtypes, whereas, significant higher dose was needed in older aged groups than younger groups. The average of optimal daily dose for response for the subjects aged above 12 years old was 46.38±15.52 per day (0.81±0.28 mg/kg/d) compared to younger groups (p<0.01). No serious adverse effects were reported and the dose did not have a significant effect on adverse effects. CONCLUSION: Optimal mean dose of OROS-MPH was significantly different by age groups. Higher dose was needed in older aged groups than younger groups. Effectiveness and tolerability of OROS-MPH in symptoms of ADHD is sustained for up to 12 weeks. |
format | Online Article Text |
id | pubmed-3440475 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Korean Neuropsychiatric Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-34404752012-09-19 Titrating Optimal Dose of Osmotic-Controlled Release Oral Delivery (OROS)-Methylphenidate and Its Efficacy and Safety in Korean Children with ADHD: A Multisite Open Labeled Study Song, Dong-Ho Choi, Soul Joung, Yoo Sook Ha, Eun Hye Kim, Boong-Nyun Shin, Yee-Jin Shin, Dongwon Yoo, Hee Jeong Cheon, Keun-Ah Psychiatry Investig Original Article OBJECTIVE: This study was aimed to determine effectiveness and tolerability of Osmotic-controlled Release Oral delivery (OROS) methylphenidate (MPH) and its optimal dose administered openly over a period of up to 12 weeks in drug naïve Korean children with ADHD. METHODS: Subjects (n=143), ages 6 to 18-years, with a clinical diagnosis of any subtype of ADHD were recruited from 7 medical centers in Korea. An individualized dose of OROS-MPH was determined for each subject depending on the response criteria. The subjects were assessed with several symptom rating scales in week 1, 3, 6, 9 and 12. RESULTS: 77 of 116 subjects (66.4%) achieved the criteria for response and the average of optimal daily dose for response was to 30.05±12.52 mg per day (0.90±0.31 mg/kg/d) at the end of the study. Optimal dose was not significantly different between ADHD subtypes, whereas, significant higher dose was needed in older aged groups than younger groups. The average of optimal daily dose for response for the subjects aged above 12 years old was 46.38±15.52 per day (0.81±0.28 mg/kg/d) compared to younger groups (p<0.01). No serious adverse effects were reported and the dose did not have a significant effect on adverse effects. CONCLUSION: Optimal mean dose of OROS-MPH was significantly different by age groups. Higher dose was needed in older aged groups than younger groups. Effectiveness and tolerability of OROS-MPH in symptoms of ADHD is sustained for up to 12 weeks. Korean Neuropsychiatric Association 2012-09 2012-09-06 /pmc/articles/PMC3440475/ /pubmed/22993525 http://dx.doi.org/10.4306/pi.2012.9.3.257 Text en Copyright © 2012 Korean Neuropsychiatric Association http://creativecommons.org/licenses/by-nc/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Song, Dong-Ho Choi, Soul Joung, Yoo Sook Ha, Eun Hye Kim, Boong-Nyun Shin, Yee-Jin Shin, Dongwon Yoo, Hee Jeong Cheon, Keun-Ah Titrating Optimal Dose of Osmotic-Controlled Release Oral Delivery (OROS)-Methylphenidate and Its Efficacy and Safety in Korean Children with ADHD: A Multisite Open Labeled Study |
title | Titrating Optimal Dose of Osmotic-Controlled Release Oral Delivery (OROS)-Methylphenidate and Its Efficacy and Safety in Korean Children with ADHD: A Multisite Open Labeled Study |
title_full | Titrating Optimal Dose of Osmotic-Controlled Release Oral Delivery (OROS)-Methylphenidate and Its Efficacy and Safety in Korean Children with ADHD: A Multisite Open Labeled Study |
title_fullStr | Titrating Optimal Dose of Osmotic-Controlled Release Oral Delivery (OROS)-Methylphenidate and Its Efficacy and Safety in Korean Children with ADHD: A Multisite Open Labeled Study |
title_full_unstemmed | Titrating Optimal Dose of Osmotic-Controlled Release Oral Delivery (OROS)-Methylphenidate and Its Efficacy and Safety in Korean Children with ADHD: A Multisite Open Labeled Study |
title_short | Titrating Optimal Dose of Osmotic-Controlled Release Oral Delivery (OROS)-Methylphenidate and Its Efficacy and Safety in Korean Children with ADHD: A Multisite Open Labeled Study |
title_sort | titrating optimal dose of osmotic-controlled release oral delivery (oros)-methylphenidate and its efficacy and safety in korean children with adhd: a multisite open labeled study |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3440475/ https://www.ncbi.nlm.nih.gov/pubmed/22993525 http://dx.doi.org/10.4306/pi.2012.9.3.257 |
work_keys_str_mv | AT songdongho titratingoptimaldoseofosmoticcontrolledreleaseoraldeliveryorosmethylphenidateanditsefficacyandsafetyinkoreanchildrenwithadhdamultisiteopenlabeledstudy AT choisoul titratingoptimaldoseofosmoticcontrolledreleaseoraldeliveryorosmethylphenidateanditsefficacyandsafetyinkoreanchildrenwithadhdamultisiteopenlabeledstudy AT joungyoosook titratingoptimaldoseofosmoticcontrolledreleaseoraldeliveryorosmethylphenidateanditsefficacyandsafetyinkoreanchildrenwithadhdamultisiteopenlabeledstudy AT haeunhye titratingoptimaldoseofosmoticcontrolledreleaseoraldeliveryorosmethylphenidateanditsefficacyandsafetyinkoreanchildrenwithadhdamultisiteopenlabeledstudy AT kimboongnyun titratingoptimaldoseofosmoticcontrolledreleaseoraldeliveryorosmethylphenidateanditsefficacyandsafetyinkoreanchildrenwithadhdamultisiteopenlabeledstudy AT shinyeejin titratingoptimaldoseofosmoticcontrolledreleaseoraldeliveryorosmethylphenidateanditsefficacyandsafetyinkoreanchildrenwithadhdamultisiteopenlabeledstudy AT shindongwon titratingoptimaldoseofosmoticcontrolledreleaseoraldeliveryorosmethylphenidateanditsefficacyandsafetyinkoreanchildrenwithadhdamultisiteopenlabeledstudy AT yooheejeong titratingoptimaldoseofosmoticcontrolledreleaseoraldeliveryorosmethylphenidateanditsefficacyandsafetyinkoreanchildrenwithadhdamultisiteopenlabeledstudy AT cheonkeunah titratingoptimaldoseofosmoticcontrolledreleaseoraldeliveryorosmethylphenidateanditsefficacyandsafetyinkoreanchildrenwithadhdamultisiteopenlabeledstudy |